News
-
ReCode Therapeutics said that it has initiated a Phase 1 clinical trial of its RCT1100 nebulized mRNA-based therapeutic, which the company is developing for the treatment of primary ciliary dyskinesia (PCD) caused by certain genetic… Read more . . .
-
The Lonza Small Molecules facility in Tampa, FL, USA has upgraded its powder analysis capabilities, the company said. In May 2022, Lonza announced that it was expanding its dry powder testing facilities in Tampa in… Read more . . .
-
Device maker Nemera and Nelson Labs have announced the expansion of an existing partnership, with Nelson Labs performing microbiological and chemical analyses, extractables and leachables testing, and biocompatibility studies for Nemera customers. Nemera is an… Read more . . .
-
Utuly intranasal epinephrine developer Bryn Pharma has named Sandy Loreaux as CEO, succeeding David Dworaczyk, who will remain with the company as head of R&D, regulatory, and production. Loreaux was most recently US President of… Read more . . .
-
Iliad Biotechnologies announced that it has published data from a Phase 2b challenge study of its BPZE1 live-attenuated intranasal pertussis vaccine and said that the vaccine induced nasal mucosal and serum immune responses, with 90%… Read more . . .
-
The FDA has approved Pfizer’s Zavzpret zavegepant (BHV-3500) calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the treatment of migraine. Pfizer said that it expects to launch Zavzpret in July 2023. The FDA accepted… Read more . . .
-
The FDA has approved Amphastar Pharmaceuticals’ NDA for 4 mg intranasal naloxone for the treatment of opioid overdose. According to the company, the nasal spray is delivered via a proprietary delivery device. A previous Amphastar… Read more . . .
-
According to Acorda Therapeutics, Esteve Pharmaceuticals has launched Acorda’s Inbrija inhaled dry powder levodopa in Spain. Acorda announced the Spanish distribution deal with Esteve in July 2021. Inbrija DPI has been approved in Europe for… Read more . . .
-
AuraVax Therapeutics, which is developing intranasal antiviral technology licensed from Massachusetts General Hospital and the University of Houston, has named former Merck executive Joseph C. Sullivan as the company’s first CEO. Sullivan was most recently Chief… Read more . . .
-
NeOnc Technologies has announced plans to develop its NEO100 intranasal perillyl alcohol for the treatment of high-grade gliomas in children. In 2016, NeOnc initiated a Phase 1/2a trial of NEO100 in adults with glioblastoma multiforme;… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan